Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL637778 | 1.00 | CHRM1 (0.40) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL25676073 | 1.00 | CHRM1 (0.40) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL11130497 | 0.86 | CHRM1 (0.46) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL4055686 | 0.85 | GPR84 (0.50) | GPR84FFAR1CA1CA2 | |
| SCHEMBL25676070 | 0.85 | GPR84 (0.50) | GPR84FFAR1CA1CA2 | |
| SCHEMBL25676077 | 0.85 | GPR84 (0.50) | GPR84FFAR1CA1CA2 | |
| SCHEMBL27050890 | 0.81 | GPR84 (0.63) | GPR84FFAR1CA1 | |
| SCHEMBL25834791 | 0.81 | GPR84 (0.63) | GPR84FFAR1CA1 | |
| SCHEMBL107486 | 0.80 | CHRM1 (0.37) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL25732985 | 0.79 | THRB (0.33) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463374-A2 | Isolated alcohol dehydrogenase enzymes and uses thereof | Bio Architecture Lab, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| EP-2195440-A2 | BIOFUEL PRODUCTION | Bio Architecture Lab, Inc. (US) | 2010-06-16 | — | — | EP | claimed |
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | claimed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | claimed |
| WO-2009046375-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| WO-2009046370-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| EP-3230463-B2 | RAPID PRETREATMENT | APALTA PATENTS OUE (EE) | 2025-07-16 | — | — | EP | disclosed |
| US-20240425893-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2024-12-26 | — | — | US | disclosed |
| US-12054761-B2 | Rapid pretreatment | Apalta Patents OÜ (EE) | 2024-08-06 | — | — | US | disclosed |
| US-11821047-B2 | High pressure zone formation for pretreatment | Apalta Patent OÜ (EE) | 2023-11-21 | — | — | US | disclosed |
| US-20230295678-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2023-09-21 | — | — | US | disclosed |
| US-11673907-B2 | Modular synthesis of aminoglycosides | REVAGENIX, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230167148-A1 | MODULAR SYNTHESIS OF AMINOGLYCOSIDES | REVAGENIX, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20040077553-A1 | Prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1404324-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040006132-A1 | Prodrugs of gaba analogs, compositions and uses thereof | ARBOR PHARMACEUTICALS, LLC | 2004-01-08 | — | — | US | disclosed |
| WO-2003077902-A1 | METHODS FOR SYNTHESIS OF PRODRUGS FROM 1-ACYL-ALKYL DERIVATIVES AND COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2003-09-18 | — | — | US | disclosed |
| US-20030171303-A1 | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof | ARBOR PHARMACEUTICALS, LLC | 2003-09-11 | — | — | US | disclosed |
| WO-2002100347-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673907-B2 | Modular synthesis of aminoglycosides | MRPL21, COASY, AARS1 | CHRM1 4778/4885AKR1A1 3540/4885CHRM3 4760/4885 |
| US-20040077553-A1 | Prodrugs of GABA analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | CHRM1 1782/4885AKR1A1 492/4885CHRM3 951/4885 |
| US-20040006132-A1 | Prodrugs of gaba analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | CHRM1 1782/4885AKR1A1 492/4885CHRM3 951/4885 |
| US-20230167148-A1 | MODULAR SYNTHESIS OF AMINOGLYCOSIDES | MRPL21, COASY, AARS1 | CHRM1 4778/4885AKR1A1 3540/4885CHRM3 4760/4885 |
| US-20090139134-A1 | BIOFUEL PRODUCTION | MGAM, DCXR, MANBA | CHRM1 3468/4885AKR1A1 694/4885CHRM3 2152/4885 |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | CHRM1 1782/4885AKR1A1 492/4885CHRM3 951/4885 |
| US-20030171303-A1 | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof | AADAC, UGT1A1, AGPAT5 | CHRM1 3125/4885AKR1A1 241/4885CHRM3 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.